Pasithea therapeutics announces positive initial safety, tolerability, pharmacokinetic (pk), and preliminary efficacy data from its phase 1 clinical trial of pas-004 in advanced cancer

-- single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on drug into 6th dosing cycle -- -- no treatment-related adverse events (traes) or dose-limiting toxicities (dlts) observed to date, including no rash or gastrointestinal (gi) aes -- -- systemic exposure at steady-state enables constant target inhibition while avoiding peak plasma toxicities -- -- half-life of approximately 70 hours supports once-daily or less frequent oral dosing -- -- distinctive mek inhibitor profile for the treatment of both nf1-related plexiform and cutaneous neurofibromas, cancer, and other opportunities -- miami, sept. 26, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor, for the treatment of neurofibromatosis type 1 (nf1) and other cancer indications, today announced safety, tolerability, pharmacokinetic (pk) and preliminary efficacy data from the first 2 cohorts of patients (n=6) in its phase 1 clinical trial of pas-004, being conducted at four clinical sites in the united states.
KTTA Ratings Summary
KTTA Quant Ranking